Autologous adipose stem cells lend themselves well to theengineering of bladder smooth muscle and may eventually make theuse of gastrointestinal tissue for this purpose obsolete, say theauthors of an animal study from UCLA. The group reports that it hasshown, for the first time, that adipose stem cells can bedifferentiated into functional smooth muscle.
Autologous adipose stem cells lend themselves well to the engineering of bladder smooth muscle and may eventually make the use of gastrointestinal tissue for this purpose obsolete, say the authors of an animal study from UCLA. The group reports that it has shown, for the first time, that adipose stem cells can be differentiated into functional smooth muscle.
"The advantage of using stem cells is that they are pluripotent and capable of forming multiple tissue types, including smooth muscle," said Larissa V. Rodríguez, MD. "The particular advantage of using adipose stem cells is that it makes this an autologous model, and therefore there is no need for immunosuppression."
The researchers processed adipose stem cells (ASCs) from human lipospirate. ASCs were then differentiated into smooth muscle phenotype (SM-ASCs) using smooth muscle-inductive cultured media.
A group of 45 female nude rats underwent laparotomy, removal of bladder dome, and repair using partial cystectomy, unseeded scaffold, or scaffold seeded with SM-ASCs. Follow-up over 12 weeks showed that tissue-engineered rats maintained smooth muscle mRNA and protein in vitro, along with bladder capacity and compliance at all follow-up points in vivo. Animals given unseeded scaffold, meanwhile, lost capacity over time and experienced poor compliance. Lower bladder volume was also seen in the cystectomy group.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.